Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.77 |
| ▸ | NPC1 | O15118 | 11/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.76 |
| ▸ | PIM1 | P11309 | 1/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.76 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.76 |
| ▸ | FLT3 | P36888 | 1/20 | 0.76 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.76 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | GBA1 | P04062 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30418675 | 1.00 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL9317689 | 0.86 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2ADORA3PIM1 | |
| SCHEMBL27568748 | 0.86 | NPC1 (0.69) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL9750118 | 0.84 | NPC1 (0.81) | RAB9ANPC1SMN1; SMN2ADORA3PIM1 | |
| SCHEMBL25403693 | 0.83 | GAA (0.71) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4119172 | 0.83 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL24008310 | 0.83 | NPC1 (0.69) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL27285455 | 0.81 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL11173864 | 0.81 | RAB9A (0.75) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL14324763 | 0.81 | NPC1 (0.76) | RAB9ANPC1SMN1; SMN2KDM4EADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624152-B2 | Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-09-23 | — | — | US | claimed |
| US-20030083267-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2003-05-01 | — | — | US | claimed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | claimed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | claimed |
| US-20060166866-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-7001921-B1 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| US-6624152-B2 | Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030083267-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2003-05-01 | — | — | US | disclosed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | disclosed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | RAB9A 1779/4885NPC1 2649/4885SMN1; SMN2 3410/4885 |
| US-20030083267-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | RAB9A 1779/4885NPC1 2649/4885SMN1; SMN2 3410/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | RAB9A 1779/4885NPC1 2649/4885SMN1; SMN2 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.